US Pharma MarketingAtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal
More details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from its
More details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition.
In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from its
Source: Endpoints News